Matching for HLA-DR excluding diabetogenic HLA-DR3 and HLA-DR4 predicts insulin independence after pancreatic islet transplantation.
HLA
HLA-DR3
HLA-DR4
Human leukocyte antigen
insulin
insulin independence
islet transplantation
type 1 diabetes
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2023
2023
Historique:
received:
28
11
2022
accepted:
16
02
2023
medline:
10
4
2023
entrez:
7
4
2023
pubmed:
8
4
2023
Statut:
epublish
Résumé
In pancreatic islet transplantation, the exact contribution of human leukocyte antigen (HLA) matching to graft survival remains unclear. Islets may be exposed to allogenic rejection but also the recurrence of type 1 diabetes (T1D). We evaluated the HLA-DR matching, including the impact of diabetogenic HLA-DR3 or HLA-DR4 matches. We retrospectively examined the HLA profile in 965 transplant recipients and 2327 islet donors. The study population was obtained from patients enrolled in the Collaborative Islet Transplant Registry. We then identified 87 recipients who received a single-islet infusion. Islet-kidney recipients, 2nd islet infusion, and patients with missing data were excluded from the analysis (n=878). HLA-DR3 and HLA-DR4 were present in 29.7% and 32.6% of T1D recipients and 11.6% and 15.8% of the donors, respectively. We identified 52 T1D islet recipients mismatched for HLA-DR (group A), 11 with 1 or 2 HLA-DR-matches but excluding HLA-DR3 and HLA- DR4 (group B), and 24 matched for HLA-DR3 or HLA-DR4 (group C). Insulin-independence was maintained in a significantly higher percentage of group B recipients from year one through five post-transplantation (p<0.01). At five-year post-transplantation, 78% of group B was insulin-independent compared to 24% (group A) and 35% (group C). Insulin-independence correlated with significantly better glycemic control (HbA1c <7%), fasting blood glucose, and reduced severe hypoglycemic events. Matching HLA-A-B-DR (≥3) independently of HLA- DR3 or HLA-DR4 matching did not improve graft survival. This study suggests that matching HLA-DR but excluding the diabetogenic HLA-DR3 and/or 4 is a significant predictor for long-term islet survival.
Identifiants
pubmed: 37026004
doi: 10.3389/fimmu.2023.1110544
pmc: PMC10070978
doi:
Substances chimiques
HLA-DR3 Antigen
0
HLA-DR4 Antigen
0
Insulin
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1110544Subventions
Organisme : HSRD VA
ID : I50 HX001229
Pays : United States
Organisme : NIDDK NIH HHS
ID : K23 DK099440
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK133709
Pays : United States
Organisme : NIDDK NIH HHS
ID : UC4 DK114839
Pays : United States
Informations de copyright
Copyright © 2023 Ballou, Barton, Payne, Berney, Villard, Meier, Baidal, Alejandro, Robien, Eggerman, Kamoun and Muller.
Déclaration de conflit d'intérêts
Authors CB, FB and EP were employed by The EMMES Company, LLC. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Transpl Int. 2021 Dec;34(12):2803-2815
pubmed: 34644422
Trends Immunol. 2016 Nov;37(11):724-737
pubmed: 27614798
Transplantation. 1991 Oct;52(4):662-7
pubmed: 1926346
Rev Immunogenet. 1999;1(3):334-42
pubmed: 11256424
Kidney Int. 2014 Nov;86(5):1039-48
pubmed: 24717292
Hum Immunol. 2008 Sep;69(9):580-7
pubmed: 18657583
Diabetes Care. 2016 Jul;39(7):1230-40
pubmed: 27208344
Transpl Int. 2020 Nov;33(11):1516-1528
pubmed: 32852857
Am J Transplant. 2016 Aug;16(8):2401-12
pubmed: 26814363
Am J Transplant. 2013 Apr;13(4):1093-1097
pubmed: 23398948
N Engl J Med. 2006 Sep 28;355(13):1397-9
pubmed: 17005967
Am J Transplant. 2016 Jan;16(1):235-45
pubmed: 26317167
Transplantation. 2007 Jul 27;84(2):137-43
pubmed: 17667803
Front Genet. 2021 Jun 30;12:670844
pubmed: 34276777
Transplantation. 2013 Sep 15;96(5):438-44
pubmed: 23902991
Diabetes Care. 2017 Aug;40(8):1065-1072
pubmed: 28701370
Nephrol Dial Transplant. 2005 May;20 Suppl 2:ii48-53, ii62
pubmed: 15814550
Transplantation. 1996 Apr 27;61(8):1272-4
pubmed: 8610431
Am J Transplant. 2021 Nov;21(11):3725-3733
pubmed: 33961335
Diabetes. 2015 Jan;64(1):172-82
pubmed: 25157096
J Clin Pathol. 2010 Jan;63(1):21-5
pubmed: 20026701
Am J Transplant. 2019 Jun;19(6):1852-1858
pubmed: 30801971
Diabetologia. 2021 Oct;64(10):2258-2265
pubmed: 34272580
Diabetes. 2010 Jul;59(7):1561-71
pubmed: 20587799
Self Nonself. 2011 Jan;2(1):26-34
pubmed: 21776332
Diabetes Care. 2021 Jun 23;:
pubmed: 34162665
J Autoimmun. 1996 Jun;9(3):379-83
pubmed: 8816974
Diabetes. 2002 Nov;51(11):3202-10
pubmed: 12401711
Diabetes Care. 2018 Sep;41(9):1887-1894
pubmed: 30002199
Diabetes Care. 2013 May;36(5):1384-95
pubmed: 23589542
Clin Nephrol. 2002 Jan;57(1):27-37
pubmed: 11837799
Transplantation. 2011 Feb 15;91(3):360-6
pubmed: 21344706
Int Immunol. 2009 Jun;21(6):705-13
pubmed: 19461125
Diabetes Care. 2011 Sep;34(9):1897-901
pubmed: 21750277
Transplantation. 2015 Apr;99(4):e31-2
pubmed: 25827326
Transplantation. 2009 Dec 15;88(11):1286-93
pubmed: 19996928
Front Immunol. 2016 Dec 07;7:575
pubmed: 28003816
Diabetes Care. 2012 Jul;35(7):1436-45
pubmed: 22723582